LENSAR, Inc. (LNSR)
$
13.58
Key metrics
Financial statements
Free cash flow per share
-0.3438
Market cap
161.4 Million
Price to sales ratio
2.8289
Debt to equity
-0.1117
Current ratio
1.8100
Income quality
0.0690
Average inventory
13.4 Million
ROE
-5.2781
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
LENSAR, Inc. is a commercial-stage medical device company, established in 2004 and headquartered in Orlando, Florida, that specializes in the design, development, and marketing of a femtosecond laser system aimed at treating cataracts and managing pre-existing or surgically induced corneal astigmatism. The company's LENSAR Laser System employs a variety of proprietary technologies to assist surgeons in achieving optimal visual outcomes, enhancing efficiency, and ensuring reproducibility through advanced imaging, procedure planning, design, and precision. The financial data pertains to the fiscal year 2024 where the company's gross profit stands at $25,851,000.00 highlighting the company's profitability from core operations. However, the cost of revenue for the company is $27,643,000.00 showcasing its production and operational expenses. Additionally, the company incurred an income tax expense of $0.00 indicating its tax obligations. The company's stock is identified with the symbol 'LNSR' in the market. The stock is affordable at $13.58 making it an appealing option for budget-conscious investors. Currently, the stock exhibits a low average trading volume of 182,090.00 indicating lower market activity. With a market capitalization of $161,669,900.00 LENSAR is classified as a small-cap player within the market. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth. This combination of factors positions LENSAR, Inc. as a noteworthy entity in its field, balancing affordability and investment potential while actively seeking to enhance medical practices related to eye care.
Is LENSAR, Inc. (LNSR) a good investment?
Investing in LENSAR, Inc. (LNSR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is LENSAR, Inc. (LNSR)'s stock forecast?
Analysts predict LENSAR, Inc. stock to fluctuate between $3.50 (low) and $17.31 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is LENSAR, Inc.'s market capitalization?
As of 2025-05-29, LENSAR, Inc.'s market cap is $161,669,900, based on 11,905,000 outstanding shares.
How does LENSAR, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, LENSAR, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy LENSAR, Inc. (LNSR) stock?
To buy LENSAR, Inc. (LNSR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LNSR. Place an order (Market, Limit, etc.).
What is the best time to invest in LENSAR, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did LENSAR, Inc. perform in the last earnings report?
Revenue: $53,494,000 | EPS: -$2.73 | Growth: 108.40%.
Where can I find LENSAR, Inc.'s investor relations reports?
Visit https://www.lensar.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for LENSAR, Inc.?
You can explore historical data from here
What is the all-time high and low for LENSAR, Inc. stock?
All-time high: $17.31 (2025-03-19) | All-time low: $1.80 (2023-11-08).
What are the key trends affecting LENSAR, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
22 days ago
14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025
businesswire.com
2 months ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.
zacks.com
2 months ago
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
prnewswire.com
2 months ago
NEW YORK , March 24, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating LENSAR, Inc. (NASDAQ: LNSR ), relating to the proposed merger with Alcon.
businesswire.com
2 months ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, LENSAR shareholders will receive only $14.00 per share in cash (an aggregate implied value of approximately $3.
businesswire.com
2 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LENSAR, Inc. (NASDAQ: LNSR) to Alcon for $14.00 per share in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, is fair to LENSAR shareholders. Halper Sadeh encourages LENSAR shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper.
globenewswire.com
3 months ago
ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company's common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
seekingalpha.com
3 months ago
LENSAR, Inc. (NASDAQ:LNSR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning and thank you for your participation. At this time, all participants are in listen-only mode.
globenewswire.com
3 months ago
31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on key operational initiatives.
globenewswire.com
3 months ago
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights.
See all news
